Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:ELTX NASDAQ:PHAT NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.27-0.3%$3.32$2.70▼$4.72$626.29M0.86662,202 shs553,477 shsELTXElicio Therapeutics$9.98+1.7%$0.00$0.00▼$0.00$159.65M1.1837,983 shs21,884 shsPHATPhathom Pharmaceuticals$8.35-2.2%$8.33$2.21▼$19.71$582.95M0.45911,990 shs501,927 shsTYRATyra Biosciences$10.37-5.1%$10.10$6.42▼$29.60$550.54M1.08226,927 shs283,932 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%+1.55%+1.08%-8.91%-13.26%ELTXElicio Therapeutics+1.73%+0.91%+27.13%+81.45%+92.66%PHATPhathom Pharmaceuticals0.00%-13.29%-4.73%+202.54%-29.36%TYRATyra Biosciences0.00%-6.24%+3.75%-4.51%-53.20%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.1737 of 5 stars3.51.00.00.01.82.50.6ELTXElicio Therapeutics1.8793 of 5 stars3.51.00.00.00.01.70.6PHATPhathom Pharmaceuticals2.6585 of 5 stars3.52.00.00.00.05.00.6TYRATyra Biosciences1.6482 of 5 stars3.50.00.00.01.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5068.20% UpsideELTXElicio Therapeutics 3.00Buy$13.0030.26% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.50109.58% UpsideTYRATyra Biosciences 3.00Buy$30.83197.33% UpsideCurrent Analyst Ratings BreakdownLatest ELTX, ABUS, PHAT, and TYRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025ELTXElicio TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $13.007/1/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/9/2025PHATPhathom PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $17.006/9/2025PHATPhathom PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025PHATPhathom PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.005/21/2025TYRATyra BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$33.00(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M101.51N/AN/A$0.51 per share6.41ELTXElicio Therapeutics$2.30M69.43N/AN/A($1.03) per share-9.69PHATPhathom Pharmaceuticals$55.25M10.55N/AN/A($3.71) per share-2.25TYRATyra BiosciencesN/AN/AN/AN/A$6.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)ELTXElicio Therapeutics-$51.90M-$6.950.00N/AN/AN/AN/A-185.70%N/APHATPhathom Pharmaceuticals-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/7/2025 (Estimated)TYRATyra Biosciences-$86.48M-$1.63N/AN/AN/AN/A-26.90%-25.54%8/6/2025 (Estimated)Latest ELTX, ABUS, PHAT, and TYRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ABUSArbutus Biopharma-$0.02N/AN/AN/A$2.21 millionN/A8/7/2025Q2 2025PHATPhathom Pharmaceuticals-$0.76N/AN/AN/A$35.58 millionN/A8/6/2025Q2 2025TYRATyra Biosciences-$0.53N/AN/AN/AN/AN/A5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/13/2025Q1 2025ELTXElicio Therapeutics-$0.67-$0.87-$0.20-$0.87N/AN/A5/8/2025Q1 2025TYRATyra Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AELTXElicio TherapeuticsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus Biopharma0.046.016.01ELTXElicio TherapeuticsN/A1.831.83PHATPhathom PharmaceuticalsN/A3.583.54TYRATyra BiosciencesN/A22.7822.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%ELTXElicio Therapeutics35.03%PHATPhathom Pharmaceuticals99.01%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%ELTXElicio Therapeutics50.90%PHATPhathom Pharmaceuticals23.00%TYRATyra Biosciences15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.53 million152.65 millionOptionableELTXElicio TherapeuticsN/A16.00 million7.86 millionNot OptionablePHATPhathom Pharmaceuticals11069.81 million53.76 millionOptionableTYRATyra Biosciences2053.09 million45.02 millionOptionableELTX, ABUS, PHAT, and TYRA HeadlinesRecent News About These CompaniesTyra Biosciences, Inc. (NASDAQ:TYRA) Sees Significant Growth in Short InterestAugust 2 at 4:31 PM | marketbeat.comTyra Biosciences (TYRA) to Release Quarterly Earnings on WednesdayJuly 31 at 6:14 AM | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.83 Consensus Target Price from BrokeragesJuly 29, 2025 | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Buy" by BrokeragesJuly 26, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Trading Down 3% - Here's WhyJuly 23, 2025 | marketbeat.comTyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call SeriesJuly 21, 2025 | prnewswire.comTyra Biosciences (NASDAQ:TYRA) Trading Up 5.7% - Should You Buy?July 16, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Stock Price Down 4.9% - What's Next?July 15, 2025 | marketbeat.comTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - MorningstarJuly 9, 2025 | morningstar.comMTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025July 8, 2025 | prnewswire.comTyra Biosciences (NASDAQ:TYRA) Shares Down 3.3% - What's Next?July 3, 2025 | marketbeat.comTyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deTYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBCJuly 2, 2025 | targetedonc.comTTyra Biosciences begins patient dosing in phase 2 study of TYRA-300 in low-grade intermediate risk non-muscle invasive bladder cancerJuly 1, 2025 | pharmabiz.comPTyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)June 30, 2025 | prnewswire.comInsider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells 9,568 Shares of StockJune 21, 2025 | insidertrades.comTyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in StockJune 17, 2025 | insidertrades.comTyra Biosciences to Participate at Upcoming Investor ConferencesMay 12, 2025 | prnewswire.comOne Tyra Biosciences Insider Raised Stake By 284% In Previous YearMay 9, 2025 | finance.yahoo.comTyra Biosciences Reports First Quarter 2025 Financial Results and HighlightsMay 8, 2025 | prnewswire.comWhy Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%May 6, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeELTX, ABUS, PHAT, and TYRA Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.27 -0.01 (-0.30%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.28 +0.00 (+0.15%) As of 08/1/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Elicio Therapeutics NASDAQ:ELTXAngion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.Phathom Pharmaceuticals NASDAQ:PHAT$8.35 -0.19 (-2.22%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.40 +0.05 (+0.59%) As of 08/1/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Tyra Biosciences NASDAQ:TYRA$10.37 -0.56 (-5.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.37 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.